Killing Part D Rebates For Duals Could Cost Pharma Another $12 Billion
This article was originally published in The Pink Sheet Daily
Executive Summary
As health care reform approaches a House-Senate conference, there is speculation that pharma will commit more money in order to keep the door closed on broader rebates.